South African pharmaceutical group Aspen Pharmacare on Tuesday reported a 21 percent decline in normalised earnings for the first half of its financial year, citing significant one-off restructuring costs linked to its sterile manufacturing operations in South Africa and France.
The company said it incurred 695 million rand (US$42.48 million) in restructuring expenses as it moves to overhaul loss-making sterile facilities. The plants manufacture drugs that must be entirely free from living microorganisms, a highly regulated and capital-intensive segment of the pharmaceutical industry.
For the six months ended December 31, normalised headline earnings per share fell to 574.8 cents, while normalised earnings before interest, tax, depreciation and amortisation (EBITDA) declined 13 percent to 5 billion rand (US$305.37 million).
Group revenue slipped 4 percent to 21.1 billion rand over the period, reflecting weakness in parts of the manufacturing division.
Aspen said the restructuring programme is “well progressed,” with cost savings expected to begin contributing positively from the second half of 2026 and to be fully realised in the 2027 financial year. The initiative is aimed at cutting fixed costs, improving capacity utilisation and restoring profitability in facilities that have struggled with lower volumes and margin pressure.
More Read
The manufacturing segment bore the brunt of the downturn. Normalised EBITDA in the overall manufacturing business plunged 85 percent to 208 million rand, while revenue in that division fell 26 percent in constant exchange rates. The company attributed the sharp decline to reduced demand and operational adjustments tied to the restructuring process.
Despite the drag from manufacturing, Aspen’s Commercial Pharmaceuticals division delivered stronger results. Revenue in the segment grew 4 percent in constant exchange rates, while normalised EBITDA increased 11 percent. The division, which is the group’s largest contributor to earnings, benefited from organic growth across injectables, over-the-counter medicines and prescription products.
Performance was supported in part by robust demand in South Africa for Mounjaro, the weight-loss treatment developed by US drugmaker Eli Lilly, which Aspen distributes locally. The company also reported an improved profit contribution from its streamlined operations in China, where it has been repositioning its product portfolio.
More Read
Aspen, founded in 1997 and headquartered in Durban, is one of Africa’s largest pharmaceutical manufacturers, with a presence in more than 100 countries. It has built its business through acquisitions and partnerships, expanding into emerging and developed markets alike. In recent years, the company has sought to rebalance its portfolio following pandemic-era volatility and changing global supply dynamics.
The sterile manufacturing segment, once seen as a growth driver, has faced challenges including fluctuating demand, high compliance costs and underutilised capacity. Analysts say the current restructuring reflects a broader strategic shift toward operational efficiency and disciplined capital allocation.
“The short-term hit to earnings is significant, but the focus will be on whether management can deliver the promised cost savings and margin recovery,” said a Johannesburg-based analyst. “The commercial business remains relatively resilient, which provides some buffer.”
Aspen’s results come amid a complex operating environment for pharmaceutical companies worldwide, as they navigate pricing pressures, currency fluctuations and evolving regulatory frameworks. In South Africa, economic headwinds and healthcare funding constraints have added to the challenges faced by domestic manufacturers.
Looking ahead, the company said it remains focused on strengthening its core commercial portfolio while stabilising the manufacturing division. Investors will be closely watching second-half performance for early signs that restructuring benefits are beginning to flow through to earnings.
